Jord BioScience Raises $7 million Series B: Biological Performance Enhancement

Jord BioScience Secures Series B Funding to Revolutionize Microbial Solutions for Agriculture - Yahoo

Index

1. Overview

2. Core Offering and Capabilities

3. Patents and Technology

4. The Product and Customer

5. Horizontal Enablement

6. Business Model

7. Final Thoughts

Overview

According to PitchBook, Jord BioScience raised $7.1 million.

The company was founded out of the University of Minnesota and continues to benefit from that relationship— the University’s tech commercialization arm helped match founder, Dr. Linda Kinkel with investors and filed the initial patents​

The U of M also became a stakeholder via its Discovery Capital Fund, which invested in Jord’s recent financing, making the university both a partner and investor).

This ongoing relationship means Jord can collaborate with university researchers for access to lab facilities, scientific expertise, or even further isolate discovery.

Core Offering and Capabilities

Jord BioScience’s core focus is on enhancing microbial performance.

Those improvements could include:

• Specific microbial strains or consortia that provide agronomic benefits.

• A mechanism to improve shelf stability, viability, or field effectiveness.

• A unique combination of active and inert ingredients that enhance microbial performance.

Ultimately, they want to improve the outcomes from microbial products in a field setting.

At it’s simplest, any problem that a bio-based product could run into, Jord could support on:

Farmer performance satisfaction with bio-based products has been one of the biggest challenges relative to synthetic products, according to data from Stratus in surverying US farmers in 2023 there was a much lower commitment to use biostimulants (one segment of biomolecules) relative to synthetic fungicide, and herbicide:

Subscribe to Upstream Ag Professional to read the rest.